| pubmed-article:6288223 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0153594 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0740345 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0026538 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C1518411 | lld:lifeskim |
| pubmed-article:6288223 | lifeskim:mentions | umls-concept:C0205221 | lld:lifeskim |
| pubmed-article:6288223 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:6288223 | pubmed:dateCreated | 1982-12-3 | lld:pubmed |
| pubmed-article:6288223 | pubmed:abstractText | Fourteen previously untreated patients with metastatic nonseminomatous germ cell cancer of the testis (NSGC) were treated with a modified VAB-4 regimen which was designed to reduce treatment-related morbidity. Nine of 10 patients with minimal disease and the only patient with advanced pulmonary disease achieved a complete response (CR) with chemotherapy alone. Two of three partial responders with advanced abdominal disease were converted to CR status with radiotherapy and/or surgery. None of the 12 CRs have relapsed (median duration of follow-up, 28+ months). We observed no granulocytopenic fever or permanent renal insufficiency. These results indicate that NSGC patients with a low tumor burden can be spared substantial toxicity without adversely affecting complete response rates. | lld:pubmed |
| pubmed-article:6288223 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6288223 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6288223 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6288223 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6288223 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6288223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6288223 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6288223 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:6288223 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:SpurrC LCL | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:CooperM RMR | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:WhiteD RDR | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:RichardsFF2nd | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:MussH BHB | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:StuartJ JJJ | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:JacksonD VDV | lld:pubmed |
| pubmed-article:6288223 | pubmed:author | pubmed-author:PaschalB RBR | lld:pubmed |
| pubmed-article:6288223 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6288223 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:6288223 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:6288223 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6288223 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6288223 | pubmed:pagination | 1742-5 | lld:pubmed |
| pubmed-article:6288223 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:meshHeading | pubmed-meshheading:6288223-... | lld:pubmed |
| pubmed-article:6288223 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:6288223 | pubmed:articleTitle | Nonseminomatous germ cell cancer of the testis. Reducing treatment-related morbidity in patients with disseminated disease. | lld:pubmed |
| pubmed-article:6288223 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6288223 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6288223 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
